CN102850403B - Water-soluble iron carbonyl compound, and preparation method and application thereof - Google Patents
Water-soluble iron carbonyl compound, and preparation method and application thereof Download PDFInfo
- Publication number
- CN102850403B CN102850403B CN201210175853.XA CN201210175853A CN102850403B CN 102850403 B CN102850403 B CN 102850403B CN 201210175853 A CN201210175853 A CN 201210175853A CN 102850403 B CN102850403 B CN 102850403B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- mercaptoethylamine
- reaction
- releasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 150000001728 carbonyl compounds Chemical class 0.000 title abstract description 8
- 229940087654 iron carbonyl Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003151 mercaptamine Drugs 0.000 claims abstract description 21
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 239000003960 organic solvent Substances 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000001953 recrystallisation Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 229910021645 metal ion Inorganic materials 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 239000013110 organic ligand Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 36
- 229940125904 compound 1 Drugs 0.000 description 21
- 229910002091 carbon monoxide Inorganic materials 0.000 description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000003446 ligand Substances 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- -1 Transition metal carbonyl compounds Chemical class 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- 125000004989 dicarbonyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- PBFKVYVGYHNCGT-UHFFFAOYSA-N 1-sulfanylpropane-1,2,3-triol Chemical compound OCC(O)C(O)S PBFKVYVGYHNCGT-UHFFFAOYSA-N 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域 technical field
本发明涉及医药化学技术领域,具体涉及一种水溶性铁羰基化合物及其制备方法和在一氧化碳可控释放中的应用。The invention relates to the technical field of medicinal chemistry, in particular to a water-soluble iron carbonyl compound, a preparation method thereof and an application in controlled release of carbon monoxide.
背景技术 Background technique
一氧化碳(CO)是一种众所周知的毒性气体,但研究表明它与一氧化氮(NO)一样,是机体内一种重要的信使分子,在生物体内具有舒张血管和支气管平滑肌、抑制血小板聚集、抑制炎症反应、抗氧化、抗凋亡、抗增殖等多种生理学作用;在神经、呼吸、循环等生理过程中和抑制急性肺损伤、脏器缺血再灌注损伤、器官移植排斥反应等病理过程中也发挥着重要调节作用。Carbon monoxide (CO) is a well-known toxic gas, but studies have shown that it, like nitric oxide (NO), is an important messenger molecule in the body, which can relax blood vessels and bronchial smooth muscles, inhibit platelet aggregation, inhibit Inflammatory response, anti-oxidation, anti-apoptosis, anti-proliferation and other physiological effects; in physiological processes such as nerves, respiration, and circulation, and in pathological processes such as acute lung injury, organ ischemia-reperfusion injury, and organ transplant rejection also play an important regulatory role.
直接吸入CO气体的缺点是显而易见的:吸入的CO必须经过整个呼吸系统,再经血液循环抵达相关组织,这对于只需局部发挥作用的情况是不合适的;浓度和剂量不易控制;同时这种方法也有导致患者和医务人员意外吸入高剂量CO而中毒的风险。The disadvantages of direct inhalation of CO gas are obvious: the inhaled CO must pass through the entire respiratory system, and then reach the relevant tissues through the blood circulation, which is not suitable for the situation where only local effects are required; the concentration and dose are not easy to control; at the same time, this The method also has the risk of poisoning patients and medical staff by accidentally inhaling high doses of CO.
过渡金属羰基化合物是一类金属有机化合物,在适当的条件下其中的羰基(CO)能够离去,如光照、取代反应、氧化还原诱导等。利用金属羰基化合物的这些性质可以设计、合成一些特定的过渡金属羰基化合物,使之在合适的条件下释放CO,即一氧化碳释放剂(分子)(carbonmonoxide-releasing molecules,CORM)。以CORM经局部用药提供CO既无需通过机体代谢过程,也无需经呼吸系统;用量大小、用药时机和释放速度容易控制,同时相对于直接吸入CO也更安全。Transition metal carbonyl compounds are a class of metal-organic compounds in which the carbonyl (CO) can leave under appropriate conditions, such as light irradiation, substitution reaction, redox induction, etc. Utilizing these properties of metal carbonyl compounds, some specific transition metal carbonyl compounds can be designed and synthesized to release CO under suitable conditions, that is, carbon monoxide-releasing molecules (CORM). Using CORM to provide CO through local administration does not need to pass through the body's metabolic process or the respiratory system; the dosage, timing and release rate of the drug are easy to control, and it is also safer than direct inhalation of CO.
动物模型试验结果表明基于金属羰基化合物的CORM具有极好的应用前景。到目前为止,报道的金属羰基化合物CORM主要是基于Ru、Mn、Mo等金属元素,然而这些化合物中一些金属如Ru、Mo等并不是生物体必须元素,另外大部分化合物还普遍存在稳定性或水溶性差以及释放速率不合适等问题。因此,研究具有良好的水溶性和适度的稳定性,而且释放CO后的残余物质对机体无害的CORM对开发具有自主知识产权、低毒性的CORM新药有实际意义。The results of animal model experiments show that CORM based on metal carbonyl compounds has excellent application prospects. So far, the reported metal carbonyl compound CORM is mainly based on metal elements such as Ru, Mn, Mo, etc. However, some metals in these compounds such as Ru, Mo, etc. are not essential elements for organisms, and most of the compounds generally have stability or Problems such as poor water solubility and unsuitable release rate. Therefore, the study of CORM with good water solubility and moderate stability, and the residual substance after releasing CO is harmless to the body has practical significance for the development of new CORM drugs with independent intellectual property rights and low toxicity.
铁是许多生物体的生命必需元素,生物体对其具有完整的代谢机制,因此,以铁羰基化合物为基础的一氧化碳释放剂(CORM)可能会具有更小的毒性或没有毒性,但目前基于铁羰基化合物CORM的报道还比较少。而且这些化合物所用的配体如环戊二烯和吡喃酮及其衍生物配体、酰氧基环己二烯等并不是生物体内常见的有机分子,其代谢产物可能对机体产生不良影响。Iron is an essential element for life in many organisms, and organisms have complete metabolic mechanisms for it. Therefore, carbon monoxide releasing agents (CORMs) based on iron carbonyl compounds may have less or no toxicity, but currently iron-based There are relatively few reports on carbonyl compounds CORM. Moreover, the ligands used in these compounds, such as cyclopentadiene, pyrone and their derivative ligands, acyloxycyclohexadiene, etc., are not common organic molecules in organisms, and their metabolites may have adverse effects on the organism.
目前合成一氧化碳释放剂的传统方法为通过配体与金属离子反应组装成可释放一氧化碳的金属配合物,这类化合物合成反应所需的配体周期较长,另外进一步组装具有适度稳定性的金属配合物又有很大难度,因为化合物太稳定则不易释放一氧化碳,化合物太不稳定在合成上又不容易得到。因此研究生物兼容金属离子和配体的CORM,并寻找一种合适的释放一氧化碳的方法就具有十分重要的意义。At present, the traditional method of synthesizing carbon monoxide releasing agents is to assemble metal complexes that can release carbon monoxide through the reaction of ligands and metal ions. It is very difficult to obtain the compound, because the compound is too stable to release carbon monoxide, and the compound is too unstable to be synthesized and not easy to obtain. Therefore, it is of great significance to study the CORM of biocompatible metal ions and ligands, and to find a suitable method to release carbon monoxide.
发明内容 Contents of the invention
本发明提供了一种可释放一氧化碳的化合物,该化合物具有良好的水溶性和适度的稳定性,反应所涉及的金属离子和有机配体也都具有良好的生物兼容性,释放CO后的残余物质对机体无害或毒性较小。The invention provides a compound that can release carbon monoxide, the compound has good water solubility and moderate stability, and the metal ions and organic ligands involved in the reaction also have good biocompatibility, and the residual substance after releasing CO Harmless or less toxic to the body.
一种化合物,其结构式如式(1)所示:A kind of compound, its structural formula is as shown in formula (1):
所述化合物有如下三种同分异构体:Described compound has following three kinds of isomers:
上述三种同分异构体均可与巯基乙胺反应生成CO,达到缓慢可控释放C0的目的。The above three isomers can react with mercaptoethylamine to generate CO, achieving the purpose of slow and controllable release of CO.
本发明还提供了所述化合物的制备方法,包括:The present invention also provides a preparation method of the compound, comprising:
将Fe3(CO)12和1-巯基甘油溶于有机溶剂中,在低于120℃,优选60~80℃的条件下发生反应,至反应液呈红色,分离纯化制得所述的化合物,具体反应过程如图1所示。dissolving Fe 3 (CO) 12 and 1-mercaptoglycerol in an organic solvent, reacting at a temperature lower than 120°C, preferably 60-80°C, until the reaction liquid turns red, and then separating and purifying to obtain the compound, The specific reaction process is shown in Figure 1.
有机溶剂将原料分散在同一反应体系中,优选为四氢呋喃,四氢呋喃是中等极性的非质子溶剂,它与反应体系中的各组分不发生反应,且分子量较小,易于与产物分离。The organic solvent disperses the raw materials in the same reaction system, preferably tetrahydrofuran, which is a medium-polar aprotic solvent, which does not react with the components in the reaction system, and has a small molecular weight, which is easy to separate from the product.
合适的原料比例有助于原料的充分反应以及产物的生成,优选的,所述Fe3(CO)12和1-巯基甘油的摩尔比为1:1~2:7。Appropriate ratio of raw materials is helpful for sufficient reaction of raw materials and formation of products. Preferably, the molar ratio of Fe 3 (CO) 12 and 1-mercaptoglycerol is 1:1-2:7.
反应时间过短,反应不能够充分进行,反应时间优选为1~4小时。If the reaction time is too short, the reaction cannot proceed sufficiently, and the reaction time is preferably 1 to 4 hours.
分离纯化的过程主要是将溶剂及未反应的原料除去,优选为:先通过旋转蒸发去除反应液中的有机溶剂,然后对红色油状产物进行重结晶,该方法操作简单,而且可以保持产物稳定。The process of separation and purification is mainly to remove the solvent and unreacted raw materials. Preferably, the organic solvent in the reaction solution is removed by rotary evaporation, and then the red oily product is recrystallized. This method is simple to operate and can keep the product stable.
本发明又提供了所述化合物在缓释CO中的应用。The present invention further provides the application of the compound in the sustained release of CO.
一种缓释CO的方法,包括:将所述化合物溶于二甲亚砜中,加入巯基乙胺水溶液。A method for slow release of CO, comprising: dissolving the compound in dimethyl sulfoxide, and adding an aqueous solution of mercaptoethylamine.
优选的,所述化合物溶于二甲亚砜中的浓度为0.001mol/L~0.02mol/L。Preferably, the concentration of the compound dissolved in dimethyl sulfoxide is 0.001mol/L-0.02mol/L.
巯基乙胺的加入量影响CO的释放速度,加入量越大,释放速度越快,优选的,所述巯基乙胺水溶液的浓度为4~5mol/L,加入量为10~120μL。The amount of mercaptoethylamine added affects the release rate of CO. The larger the amount added, the faster the release rate. Preferably, the concentration of the mercaptoethylamine aqueous solution is 4-5 mol/L, and the added amount is 10-120 μL.
与现有技术相比较,本发明化合物的有益效果为:Compared with prior art, the beneficial effect of compound of the present invention is:
(1)该化合物具有良好的水性和适度的稳定性;(1) The compound has good water resistance and moderate stability;
(2)该化合物所涉及的金属离子和有机配体具有良好的生物兼容性;(2) The metal ions and organic ligands involved in the compound have good biocompatibility;
(3)该化合物释放一氧化碳的时机和速率易控。(3) The timing and rate of the compound releasing carbon monoxide are easy to control.
附图说明 Description of drawings
图1为本发明化合物1反应流程图。Fig. 1 is a flow diagram of the reaction of compound 1 of the present invention.
图2为化合物1的红外光谱图。Figure 2 is the infrared spectrum of compound 1.
图3为化合物1的核磁共振图(包含了化合物1三种异构体);其中图3a和图3b为不同时间制备的化合物1的核磁共振图谱,图3c为加了D2O后的化合物1的核磁共振图谱。Figure 3 is the NMR spectrum of compound 1 (including three isomers of compound 1); wherein Figure 3a and Figure 3b are the NMR spectra of compound 1 prepared at different times, and Figure 3c is the compound after adding D 2 O 1 NMR spectrum.
图4为化合物1加入巯基乙胺后的两种产物红外图。Fig. 4 is the infrared diagram of two products of compound 1 after adding mercaptoethylamine.
图5为加入6eq巯基乙胺后化合物1的红外变化图;其中,(a)为加入巯基乙胺后0~25min化合物1的红外变化图;(b)为加入巯基乙胺后45~175min化合物1的红外变化图。Figure 5 is the infrared change diagram of compound 1 after adding 6eq mercaptoethylamine; wherein, (a) is the infrared change diagram of compound 1 after 0~25min after adding mercaptoethylamine; (b) is the 45~175min compound after adding mercaptoethylamine 1’s infrared change map.
具体实施方式 Detailed ways
1、化合物的制备1. Preparation of compounds
在四氢呋喃(THF)中加入2.81g Fe3(CO)12和0.94g 1-巯基甘油,于70℃反应2h,获得红色溶液,旋转蒸发除去其中的溶剂(THF),然后对红色油状产物进行重结晶,所使用的溶剂为二氯甲烷/环己烷混合溶剂,最终制得纯净的红色油状物质,暂命名为化合物1。Add 2.81g Fe 3 (CO) 12 and 0.94g 1-mercaptoglycerol to tetrahydrofuran (THF), and react at 70°C for 2h to obtain a red solution, remove the solvent (THF) by rotary evaporation, and then redo the oily product. For crystallization, the solvent used was a mixed solvent of dichloromethane/cyclohexane, and finally a pure red oily substance was obtained, tentatively named compound 1.
2、化合物的表征2. Characterization of compounds
利用Varian Scimitar 600采集化合物1的红外光谱图,如图2所示,化合物1在3367cm-1(OH伸缩振动)、2876,2928cm-1(CH2伸缩振动)、1415cm-1(CH2弯曲振动)、1992~2073cm-1(C=O伸缩振动)、1262~1334cm-1(OH面内弯曲)、561~617cm-1(OH面外弯曲)、1031~1071cm-1(C-O伸缩振动)有明显的吸收峰,可以证实化合物1中含OH、CH2、C=O及C-O结构。Varian Scimitar 600 was used to collect the infrared spectrum of compound 1, as shown in Figure 2, compound 1 was at 3367cm -1 (OH stretching vibration), 2876, 2928cm -1 (CH 2 stretching vibration), 1415cm -1 (CH 2 bending vibration ), 1992~2073cm -1 (C=O stretching vibration), 1262~1334cm -1 (OH in-plane bending), 561~617cm -1 (OH out-of-plane bending), 1031~1071cm -1 (CO stretching vibration) The obvious absorption peaks can confirm that compound 1 contains OH, CH 2 , C=O and CO structures.
图3为化合物1的核磁共振图谱,它包含了三种异构体的结构信息,三种同分异构体的结构式为:Figure 3 is the nuclear magnetic resonance spectrum of compound 1, which contains the structural information of three isomers, and the structural formulas of the three isomers are:
在化合物1中桥连巯基甘油存着三种构型,两个顺式(aa)、一顺一反(ae)、两个反式(ee),在配体部分aa构型的化合物是对称结构,在1HNMR中OH有两种峰存在,分别是两重峰和三重峰,ae构型有四种峰,分别是两个两重峰和两个三重峰,ee构型也是对称结构,也同样有两种峰存在,分别是两重峰和三重峰,所以两重峰和三重峰的比值是1:1。There are three configurations of bridged mercaptoglycerol in compound 1, two cis (aa), one cis-trans (ae), two trans (ee), and the compound with aa configuration in the ligand part is symmetrical Structure, OH has two peaks in 1 HNMR, which are doublets and triplets. There are four peaks in the ae configuration, which are two doublets and two triplets. The ee configuration is also a symmetrical structure. There are also two peaks, doublet and triplet, so the ratio of doublet to triplet is 1:1.
同样从结构式可推出O-H和C-H的比值是2:5,根据图3a和3b可知化合物1有四种两重峰和两种五重峰,两个五重峰是由四个三重峰耦合得到,两重峰和五重峰的比例为1:1,由于图3a和3b是在不同时间制备出,在环境上有细微的差异因此三种异构体的比例不同。当往3b的化合物中加入一滴D2O时核磁变成了图3c,OH峰消失,同时水峰也移动,结合图3b计算出O-H和C-H的比值是7.38:19.68≈2:5。It can also be deduced from the structural formula that the ratio of OH to CH is 2:5. According to Figures 3a and 3b, it can be seen that compound 1 has four doublets and two quintets, and the two quintets are obtained by coupling four triplets. The ratio of the doublet and the quintet is 1:1. Since Figures 3a and 3b were prepared at different times, there are slight differences in the environment, so the ratios of the three isomers are different. When a drop of D 2 O is added to the compound of 3b, the NMR changes to Figure 3c, the OH peak disappears, and the water peak also moves. Combined with Figure 3b, the ratio of OH to CH is calculated to be 7.38:19.68≈2:5.
3、化合物的应用3. Application of compounds
将制备的化合物1(17mg,34mmol)加入3mL DMSO,溶解后加入反应管中,37℃下分别加入20(3eq)、40(6eq)、80(12eq)μL巯基乙胺(1g/2.5ml)水溶液,每隔一段时间测一次红外(Varian Scimitar 600)。Add the prepared compound 1 (17mg, 34mmol) into 3mL DMSO, dissolve and add to the reaction tube, add 20 (3eq), 40 (6eq), 80 (12eq) μL mercaptoethylamine (1g/2.5ml) at 37°C Aqueous solution, measure infrared (Varian Scimitar 600) every once in a while.
在化合物1中加入巯基乙胺后,红外谱图发生明显变化,如图4所示,化合物1、产物1和产物2分别在2068,2031,1989cm-1(三个);2015,1974,1942,1907cm-1(四个);2004,1941cm-1(两个)有明显的羰基吸收峰,说明其分别为六羰基、五羰基和二羰基化合物。由此可知化合物1在加入巯基乙胺后羰基逐渐减少并作为一氧化碳释放出来,说明该过程可以释放一氧化碳。After adding mercaptoethylamine to compound 1, the infrared spectrum changes significantly, as shown in Figure 4, compound 1, product 1 and product 2 are respectively at 2068,2031,1989cm -1 (three); 2015,1974,1942 ,1907cm -1 (four); 2004,1941cm -1 (two) have obvious carbonyl absorption peaks, indicating that they are hexacarbonyl, pentacarbonyl and dicarbonyl compounds. It can be seen that the carbonyl group of compound 1 is gradually reduced and released as carbon monoxide after adding mercaptoethylamine, indicating that this process can release carbon monoxide.
如图5(a)所示,化合物1在加入巯基乙胺后六羰基峰逐渐减弱,五羰基峰逐渐增强,说明即化合物逐渐转化为产物1,该过程中有羰基离去,即有一氧化碳释放出来;如图5(b)所示,随着时间变化五羰基峰逐渐减弱,二羰基峰逐渐增强,说明产物1逐渐转化为产物2,该过程中有羰基离去,即有一氧化碳释放出来。As shown in Figure 5(a), the hexacarbonyl peak of compound 1 gradually weakens after the addition of mercaptoethylamine, and the pentacarbonyl peak gradually increases, indicating that the compound is gradually converted into product 1. During this process, the carbonyl group leaves, that is, carbon monoxide is released. As shown in Figure 5(b), the pentacarbonyl peak gradually weakens and the dicarbonyl peak gradually strengthens as time changes, indicating that product 1 is gradually converted into product 2, and carbonyl leaves during this process, that is, carbon monoxide is released.
表1化合物1在巯基乙胺不同比例下释放一氧化碳的半衰期Table 1 Compound 1 releases carbon monoxide half-life at different ratios of mercaptoethylamine
从表1可看出,化合物1释放一氧化碳的速率跟巯基乙胺的量有关,即随着巯基乙胺的量增大,反应速率明显加快。由此可见该化合物释放一氧化碳的速率可根据需要进行调节。It can be seen from Table 1 that the rate of release of carbon monoxide by compound 1 is related to the amount of mercaptoethylamine, that is, as the amount of mercaptoethylamine increases, the reaction rate is significantly accelerated. It follows that the rate at which this compound releases carbon monoxide can be adjusted as desired.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210175853.XA CN102850403B (en) | 2012-05-29 | 2012-05-29 | Water-soluble iron carbonyl compound, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210175853.XA CN102850403B (en) | 2012-05-29 | 2012-05-29 | Water-soluble iron carbonyl compound, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102850403A CN102850403A (en) | 2013-01-02 |
CN102850403B true CN102850403B (en) | 2015-01-14 |
Family
ID=47397430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210175853.XA Expired - Fee Related CN102850403B (en) | 2012-05-29 | 2012-05-29 | Water-soluble iron carbonyl compound, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102850403B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104814952B (en) * | 2015-04-16 | 2017-12-26 | 嘉兴学院 | A kind of method for promoting carbon monoxide emitter release carbon monoxide and preventing from being formed precipitation |
CN109134551B (en) * | 2018-06-15 | 2021-01-05 | 嘉兴学院 | Water-soluble iron carbonyl compound and preparation method and application thereof |
CN110078628B (en) * | 2019-04-03 | 2022-02-15 | 嘉兴学院 | Water-soluble iron-based carbon monoxide releasing agent and preparation method and application thereof |
CN112920225B (en) * | 2021-01-26 | 2024-04-12 | 嘉兴学院 | Sulfonate-containing water-soluble iron carbonyl compound and preparation method and application thereof |
CN113943327B (en) * | 2021-10-26 | 2023-06-20 | 嘉兴学院 | Azadiene iron carbonyl compound and its preparation and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646140A (en) * | 2002-02-04 | 2005-07-27 | 阿尔法玛药品研发有限公司 | Use of a compound having the ability to release CO in preparation of pharmaceutical compositions for treatment of inflammation |
DE102010014411A1 (en) * | 2010-04-08 | 2011-10-13 | Friedrich-Schiller-Universität Jena | New iron complexes, useful as carbon monoxide and iron releasing molecules for treating e.g. high blood pressure, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis, sepsis, angina and myocardial infarction |
DE102010014412A1 (en) * | 2010-04-08 | 2012-04-19 | Friedrich-Schiller-Universität Jena | Use of dinuclear iron complexes having sulfur-containing ligands as carbon monoxide-releasing pharmacological agents e.g. for treating hypertension, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis or sepsis |
-
2012
- 2012-05-29 CN CN201210175853.XA patent/CN102850403B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1646140A (en) * | 2002-02-04 | 2005-07-27 | 阿尔法玛药品研发有限公司 | Use of a compound having the ability to release CO in preparation of pharmaceutical compositions for treatment of inflammation |
DE102010014411A1 (en) * | 2010-04-08 | 2011-10-13 | Friedrich-Schiller-Universität Jena | New iron complexes, useful as carbon monoxide and iron releasing molecules for treating e.g. high blood pressure, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis, sepsis, angina and myocardial infarction |
DE102010014412A1 (en) * | 2010-04-08 | 2012-04-19 | Friedrich-Schiller-Universität Jena | Use of dinuclear iron complexes having sulfur-containing ligands as carbon monoxide-releasing pharmacological agents e.g. for treating hypertension, cancer, tissue damage by irradiation, post-ischemic injury, atherosclerosis or sepsis |
Non-Patent Citations (2)
Title |
---|
Graeme Hogarth等,.γ-Hydroxypropyl-functionalised iron thiolate complexes: crystal and molecular structure of [{Fe2(CO)6(l-SCH2CH2CH2OH)}2-(μ4-S)].《Transition Met Chem》.2008,第33卷第729-732页. * |
Jean-Franc¸ois Capon等,.Electrochemical and theoretical investigations of the reduction of [Fe2(CO)5L{l-SCH2XCH2S}] complexes related to [FeFe] hydrogenase.《New Journal of Chemistry》.2007,第31卷第2052-2064页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102850403A (en) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102850403B (en) | Water-soluble iron carbonyl compound, and preparation method and application thereof | |
CN100528886C (en) | Metal complex with liriodenine as ligand and its synthesis process and use | |
Latifi et al. | Drug delivery by micro and meso metal-organic frameworks | |
CN105061636B (en) | A kind of preparation method of chitosan citrate rare earth compounding | |
CN102260293B (en) | Transition metal coordination compounds with oxoglaucine as ligand, synthesizing method thereof, and application thereof | |
CN114539294B (en) | Cisplatin-resistant cell white rattan-phenanthrene Luo Linxin (II) complex for targeting human lung adenocarcinoma, synthesis method and application thereof | |
CN102391336B (en) | Compound and preparation method and use thereof | |
Wang et al. | Syntheses, characterizations, thermal stability and photoluminescence of four silver coordination polymers with mixed ligands | |
CN108084177B (en) | A kind of jamaicin 9- pyrazole derivatives and its preparation and application | |
CN111732608A (en) | A kind of manganese carbonyl compound based on o-phenanthroline, preparation method and application | |
CN109134551B (en) | Water-soluble iron carbonyl compound and preparation method and application thereof | |
CN111728981A (en) | A kind of quercetin rare earth complex and preparation method thereof | |
EP3199152B1 (en) | Anti-cancer agent and method for killing cancer cells | |
CN114573598B (en) | White She Tengxin (II) complex with high in-vivo and in-vitro activity and synthesis method and application thereof | |
Wang et al. | [Retracted] Construction of a New In (III)-Based Coordination Polymer for Selective Luminescent Detection of Cr2O72− and Anti-Bacterial Protective Effect on Staphylococcus Aureus Infection after Missed Abortion | |
CN110256482B (en) | Heteropoly vanadate compound and preparation method thereof | |
CN114702441A (en) | A kind of cuprous complex with antitumor activity and its preparation method and application | |
CN112920225B (en) | Sulfonate-containing water-soluble iron carbonyl compound and preparation method and application thereof | |
CN107243002B (en) | Preparation method of polytetracaprolactone-pentaerythritol administration nanoparticles | |
Mitkina et al. | Crystal structure and chemical oxidation of the palladium (II) cyclam complex within the cavity of cucurbit [8] uril | |
CN105801626B (en) | A kind of water soluble pegylation Fischer carbene compounds and preparation method thereof | |
Kiskin et al. | First hexanuclear manganese (II) μ6-Cl centered carboxylate anion: Synthesis, structure and magnetic properties | |
He et al. | Regulating structures of two Co (II)-based coordination polymers: Application value in sepsis therapy by inhibiting inflammatory response | |
Zhang et al. | RETRACTED: two new coordination polymers: magnetic properties and treatment activity on the wound healing after facial plastic surgery by inhibiting the vascular endothelial growth factor signaling pathway | |
AU2016101702A4 (en) | Crystalline contrast agent for magnetic resonance imaging, kit and composition comprising it and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150114 |